Treatment of cutaneous lymphomas: today and tomorrow.
There exist many skin-directed and systemic immunomodulating or cytotoxic treatment options for primary cutaneous T- and B-cell lymphomas. However, especially in advanced stages conventional therapies only end in a transient remission without curative results unable to prolong overall survival. Over the last twenty years the high need of new therapeutic strategies resulted in the development of emerging drugs targeting more tumor specific, like monoclonal antibodies, histone-deacetylase inhibitors, proteasome inhibitors, or fusion proteins. This article aims to discuss the conventional treatment modalities as well as new therapeutic strategies, which passed already through clinical trials showing promising results in the treatment of primary cutaneous lymphomas.
Mestel
D S
DS
Department of Dermatology Venereology and Allergy, Skin Cancer Center, Charité Universitaetsmedizin Berlin, Germany. dominik.mestel@charite.de
Beyer
M
M
Steinhoff
M
M
Sterry
W
W
D005544:Forecasting; D006801:Humans; D016393:Lymphoma, B-Cell / Q000628:therapy*; D009182:Mycosis Fungoides / Q000628:therapy*; D012751:Sezary Syndrome / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy*